James Howard-Tripp, CEO of Labopharm Inc. ,
Rings The NASDAQ Stock Market Closing Bell

Tuesday October 10, 2006
at NASDAQ's MarketSite
in New York City.

Labopharm Inc.
[DDSS]

James Howard-Tripp, CEO of Labopharm Inc. (DDSS) presides over the closing bell to celebrate its listing on the NASDAQ.

Labopharm Inc. (TSX:DDS) (Nasdaq:DDSS) is an international, specialty pharmaceutical company focused on the development of drugs incorporating Contramid(r), the Company's proprietary advanced controlled-release technology. Labopharm's lead in-house product, a once-daily formulation of the analgesic tramadol, has received regulatory approval in 22 European countries and commercial launch of the product across Europe is underway. In the U.S., the Company has received an Approvable Letter from the FDA and is working with its marketing partner for the U.S., Purdue Pharma, to prepare for the launch of the product upon final approval. The Company's pipeline includes a combination of in-house and partnered programs with products both in clinical trials and in preclinical development. For more information, please visit www.labopharm.com.

Reprints

Click for larger pictures of the NASDAQ MarketSite. Additional Photographs for 10/10/2006 Download Hi-Res Quality Photo of this NASDAQ Market Open - Pictured: James Howard-Tripp, CEO of Labopharm Inc., signs the podium at the Closing Bell These photos are Copyright 2006, The Nasdaq Stock Market Inc. and available for re-publication by the news media only. Any commercial use is strictly prohibited without the prior written consent of The Nasdaq Stock Market Inc. © Copyright 2006, The NASDAQ Stock Market, Inc. Reprinted with the permission of The Nasdaq Stock Market, Inc.